key: cord-0990415-lcqwrhnr
authors: Fix, Oren K.; Blumberg, Emily A.; Chang, Kyong‐Mi; Chu, Jaime; Chung, Raymond T.; Goacher, Elizabeth K.; Hameed, Bilal; Kaul, Daniel R.; Kulik, Laura M.; Kwok, Ryan M.; McGuire, Brendan M.; Mulligan, David C.; Price, Jennifer C.; Reau, Nancy S.; Reddy, K. Rajender; Reynolds, Andrew; Rosen, Hugo R.; Russo, Mark W.; Schilsky, Michael L.; Verna, Elizabeth C.; Ward, John W.; Fontana, Robert J.
title: AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID‐19 Infection in Patients with Liver Disease
date: 2021-02-12
journal: Hepatology
DOI: 10.1002/hep.31751
sha: 5c5fb15efbb49b8cd7a3ed94dd352fea4c1e26b3
doc_id: 990415
cord_uid: lcqwrhnr

BACKGROUND AND RATIONALE: The aim of this document is to provide a concise scientific review of the currently available COVID‐19 vaccines and those in development, including mRNA, adenoviral vectors, and recombinant protein approaches. The anticipated use of COVID‐19 vaccines in patients with chronic liver disease and liver transplant recipients is reviewed and practical guidance is provided for health care providers involved in the care of patients with liver disease and liver transplantation about vaccine prioritization and administration. MAIN RESULTS: The Pfizer and Moderna mRNA COVID‐19 vaccines are associated with a 94%‐95% vaccine efficacy compared to placebo against COVID‐19. Local site reactions of pain and tenderness were reported in 70%‐90% of clinical trial participants, and systemic reactions of fever and fatigue were reported in 40%‐70% of participants, but these reactions were generally mild and self‐limited and occurred more frequently in younger individuals. Severe hypersensitivity reactions related to the mRNA COVID‐19 vaccines are rare and more commonly seen in women and individuals with a history of prior drug reactions for unclear reasons. Because patients with advanced liver disease and immunosuppressed patients were excluded from the vaccine licensing trials, additional data regarding the safety and efficacy of COVID‐19 vaccines are eagerly awaited in these and other subgroups CONCLUSIONS: Remarkably safe and highly effective mRNA COVID‐19 vaccines are now available for widespread use and should be given to all adult patients with chronic liver disease and liver transplant recipients. The online companion document located at https://www.aasld.org/about‐aasld/covid‐19‐resources will be updated as additional data become available regarding the safety and efficacy of other COVID‐19 vaccines in development.

weakened immune systems from other diseases or medications may be at higher risk of death from COVID- 19 . Over the past year, over 60 Table 1 ) Double dosing or booster dosing of the HAV and HBV vaccines can increase vaccine response rates in CLD patients. (4, 5) Immunosuppressed liver transplant recipients are also known to have a lower response rate to many non-COVID-19 vaccines particularly when given early after transplant. Therefore, it is generally recommended that vaccines be given prior to transplant Accepted Article whenever possible or waiting until 3 to 6 months after transplant. The Advisory Committee on Immunization Practices (ACIP) recommends avoiding live virus vaccines in those receiving high-dose corticosteroids and other immunosuppressed individuals because of concerns of uncontrolled viral replication. ( 

Supplemental Text for additional information regarding non-COVID-19 vaccines.

 While double dosing is recommended for some non-COVID-19 vaccines in CLD patients, this approach is NOT recommended with COVID-19 vaccines.

Entry of SARS-CoV-2 requires binding of the viral spike glycoprotein to the angiotensin-converting enzyme 2 (ACE2) receptor on human epithelial cells. (7) As a result, researchers have targeted the viral spike glycoprotein to induce vaccine-mediated immune response against SARS-CoV-2 using various delivery systems. The release of the 29,903-nucleotide sequence of the SARS-CoV-2 genome on January 10, 2020 led to diagnostic testing and the development of Operation Warp Speed in the US with the goal of developing safe and effective vaccines within one year. (8, 9) Both Moderna and Pfizer-BioNTech developed a vaccine using synthetic nucleoside-modified mRNA that encodes the spike glycoprotein. (10, 11) Other vaccines that are currently in development use DNA, protein subunits, inactivated SARS-CoV-2, viral vectors, and attenuated virus. (Table 1, Figure 1 ) All of the vaccines described below are not live SARS-CoV-2 and cannot replicate, even in immunocompromised persons.

mRNA-based vaccines involve the delivery of non-infectious synthetic mRNA encoding one or more target antigens (e.g., SARS CoV-2 spike protein) that can be taken up by host cells including antigen presenting cells (e.g., dendritic cells). (Figure 1 ) Upon cytoplasmic entry, the delivered mRNA uses the host ribosomal translational machinery to make the target antigens that can be processed for cell surface expression via class I and II major histocompatibility complex or be secreted. This induces protective immunity against a future attack (e.g., from SARS-CoV-2) by priming antigen-specific cytotoxic CD8 T-cells and helper T-cells and a neutralizing antibody response from B-cells. (12) A key challenge to the mRNA vaccine platform is its stability Accepted Article and efficiency, which is related to its susceptibility to enzymatic degradation, limited cellular uptake, and capacity for innate immune activation that can inhibit mRNA translation. In recent years, these challenges have been addressed by using lipid nanoparticles that protect the mRNA from enzymatic degradation and enhance their cellular uptake and biological half-life. (13, 14) Additionally, nucleoside modifications prevent innate immune activation and degradation. Nevertheless, the mRNA-based vaccines degrade within a few hours at room temperature and require very cold temperatures during manufacturing, transportation, and storage.

Adenovirus-based vaccines use a harmless, genetically modified exogenous virus as the carrier to bring DNA that encodes the SARS-CoV-2 spike protein into the recipient's cells. Once the adenovirus enters a cell, it delivers the DNA for the SARS-CoV-2 spike protein into the nucleus and the corresponding mRNA is transcribed. Using the host cellular machinery, the mRNA is then translated into SARS-CoV-2 spike protein, which triggers the host immune response after being expressed on cell surface membranes or secreted into the serum.

There are hundreds of known adenoviruses and most do not cause disease in humans, while others cause a range of symptoms depending on the tropism of the strains. The adenovirus vector is modified to prevent it from replicating in host cells. Adenovirus-vector vaccines are stable at room temperature for prolonged periods. Prior studies have shown that replication defective chimp adenoviral vector vaccines can effectively deliver viral genes to the liver, induce a host immune response, and are safe to use in both healthy volunteers and patients with CLD. (15, 16) Early safety data were favorable in the Phase 3 clinical trial of Oxford/AstraZeneca's AZD1222 adenovirus Accepted Article expected to pose a risk to immunocompromised patients. Further guidance from regulatory and public health authorities is eagerly awaited following their authorization, and further information regarding any elevations in liver function tests (although not in patients with advanced liver disease) will be available from ongoing or recently completed large phase 3 trials.

Inactivated whole virus vaccines are made by treating the virus with heat and/or chemicals (usually formalin) to prevent its capacity to replicate but are typically given in multiple doses to induce a more robust host immune response. This technology has been used for vaccines against rabies, polio, and HAV. The See Supplemental Text for background on assays to detect immunity to COVID-19.

In December 2020, the FDA granted EUA to two mRNA vaccines to prevent COVID-19: BNT162b2 manufactured by Pfizer-BioNTech and mRNA-1273 by Moderna, respectively. ( Table 1 ) Both vaccines are based on the SARS-CoV-2 spike glycoprotein antigen encoded by mRNA in lipid nanoparticles. The spike Accepted Article glycoprotein antigen mediates binding of the virus to the ACE2 receptor on host cells to enable viral entry and replication. In both vaccines, the mRNA encodes the spike glycoprotein antigen stabilized in its pre-fusion form, which more closely resembles the intact virus. (23) VE for the Pfizer-BioNTech primary endpoint (confirmed COVID-19 occurring at least 7 days after the second dose in participants without serological or virological evidence of past SARS-CoV-2 infection) was 95.0%, while VE for the Moderna primary endpoint (COVID-19 occurring at least 14 days after the second dose in participants who were negative for SARS-CoV-2 at baseline) was 94.1%. (Figure 2 ) In both vaccines, reactogenicity and adverse events (AEs) were generally milder and less frequent in older than in younger participants and more frequent and more severe after the second dose. (Figure 3 It is unclear why the vast majority of cases of anaphylaxis occurred in women; however, more women than men received the first doses of the mRNA COVID-19 vaccines during the analytic period. (25, 26) 

This article is protected by copyright. All rights reserved

The incidence of anaphylaxis associated with the Pfizer-BioNTech vaccine may be 10 times as high (1 in 100,000) as the incidence reported with previously approved vaccines (1 in 1,000,000). (27) Polyethylene glycol (PEG), used to stabilize the lipid nanoparticles and prolong their half-life in both mRNA vaccines, has been implicated as a potential cause for anaphylaxis.

 Anyone with a history of severe or immediate allergic reaction to any vaccine components, including PEG, should NOT receive either mRNA COVID-19 vaccine. 

Only the Pfizer-BioNTech mRNA vaccine has been authorized for children <18 years of age (specifically 

Patients with stable chronic medical conditions such as compensated CLD, HIV, HBV, or HCV were eligible to participate in both the Pfizer-BioNTech and Moderna Phase 3 trials. However, those on immunosuppressive therapy were excluded.

In the Pfizer-BioNTech Phase 2/3 trial, 20.5% of study participants had a comorbidity defined by the Charlson Comorbidity Index categories, which include liver disease (8030 with a comorbidity received BNT162b2 and 8029 received placebo). VE was 95.3% in participants with comorbidities and was similar to that seen in patients without comorbidities (94.7%). Among the 214 participants (0.6%) with liver disease, 124 received BNT162b2 and 90 received placebo, but safety and efficacy data in this subgroup have not yet been reported.

In the Moderna Phase 3 trial, at least one high risk condition was present in 22.3% of the participants.

Among the 196 (0.6%) participants with liver disease, 100 received mRNA-1273 and 96 received placebo.

Since no participants with liver disease developed COVID-19, VE cannot be determined for this subgroup.

The COVID-19 vaccines are currently a limited resource that requires rational selection of the highest risk candidates for priority access. Providers must administer COVID-19 vaccines in accordance with prioritization Accepted Article groups determined by appropriate public health authorities. (38) The CDC has published a dynamic document that ranks groups at high risk for exposure or poor outcome from COVID-19 (Phases 1a, 1b, 1c, 2) . (39) Healthcare workers are prioritized by the CDC (Phase 1a) to receive the COVID-19 vaccines because of their high risk of exposure to SARS-CoV-2, the need to protect patients from infection, and the need to preserve the capacity to care for patients. (40) Patients with underlying medical conditions, including liver disease (e.g., 

This article is protected by copyright. All rights reserved  Vaccinated healthcare providers are encouraged to volunteer to assist with their local vaccination efforts.

Due to the increased mortality with COVID-19 infection in adult CLD patients and particularly those with cirrhosis, it is recommended that these patients be prioritized for COVID-19 vaccination (Phase 1c). Although safety and efficacy data with the two available mRNA vaccines in CLD patients are limited, adverse events are not anticipated to be more frequent nor is efficacy expected to be lower than the general population; however, additional prospective studies are needed.

If the supply of COVID-19 vaccine is limited, it is reasonable to prioritize patients with higher Model for End-stage Liver Disease (MELD) or Child-Turcotte-Pugh scores for vaccination or those who are anticipated to undergo imminent liver transplantation, but all CLD patients should be vaccinated whenever possible. 

This article is protected by copyright. All rights reserved  All patients with CLD, including vaccine recipients, should continue to mitigate their risk of SARS-CoV-2 exposure, e.g., masking, social distancing, hand washing, etc.

As immunocompromised patients and SOT recipients were not included in the clinical trials of vaccines against SARS-CoV-2, there is a lack of data regarding the safety and efficacy of the available vaccines in this population. Other unknowns regarding vaccination of liver transplant recipients include:

1. Efficacy of the immune response to the vaccine to prevent SARS-CoV-2 infection in SOT recipients.

2. Whether the duration of vaccine-conferred immunity differs from immunocompetent hosts. 5. The frequency of elevation of liver tests or ACR following vaccination.

6. The best choice of vaccine in this population.

Despite these uncertainties, the available mRNA COVID-19 vaccines do not contain live or attenuated virus and therefore are unlikely to pose a safety concern for immunosuppressed patients.(51) Since replication defective or non-replicating vaccines have also not yet been tested in SOT recipients or other immunosuppressed patients, additional data are needed before use of these COVID-19 vaccines can be recommended in these patients.

 COVID-19 vaccination is recommended for all SOT recipients including liver transplant recipients. 

This article is protected by copyright. All rights reserved Increasing liver disease severity has been associated with lower non-COVID-19 vaccine responsiveness. (55, 56) These large knowledge gaps related to liver disease and transplantation require special attention in further studies. (Table 2) CONCLUSION Since the identification of the SARS-CoV-2 genome in January 2020, remarkable progress has been made in the development of highly effective and generally safe mRNA vaccines for COVID-19. The CDC currently recommends that all adults over the age of 18 should receive the 2-dose mRNA vaccines according to the manufacturers' recommendations to prevent future COVID-19. Pre-and post-vaccination serological testing is not recommended because of the absence of studies regarding their impact on outcomes. Both mRNA COVID-19 vaccines are recommended for all patients with CLD (compensated or decompensated) and

immunosuppressed SOT recipients. The AASLD recommends that providers advocate for prioritizing patients with compensated or decompensated cirrhosis or liver cancer, immunosuppressed patients such as SOT recipients, and living liver donors for COVID-19 vaccination based upon local health policies, protocols, and vaccine availability.

The clinical impact of SARS-CoV-2 viral variants is rapidly evolving, and until further studies are available, COVID-19 vaccination should not be withheld or deferred in any patient because of efficacy or safety concerns aside from severe allergic reaction to any vaccine components. All COVID-19 vaccine recipients are recommended to continue social distancing, masking, frequent hand washing, and follow other exposuremitigating behaviors. The online companion document located at https://www.aasld.org/about-aasld/covid-19-resources will be updated as additional data become available regarding the safety and efficacy of other COVID-19 vaccines in development. 

Immune dysfunction and infections in patients with cirrhosis

Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis

The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

Response to vaccination against hepatitis B virus with a schedule of four 40-μg doses in cirrhotic patients evaluated for liver transplantation: factors associated with a response

Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list

ACIP general best practice guidelines for immunization

Mechanisms of coronavirus cell entry mediated by the viral spike protein

A new coronavirus associated with human respiratory disease in China

An mRNA vaccine against SARS-CoV-2 -preliminary report

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

mRNA vaccine delivery using lipid nanoparticles

Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel)

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans

Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection. Vaccines (Basel)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet

AstraZeneca's COVID-19 vaccine authorised for emergency supply in the UK

announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial. The Lancet

Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant

Novavax Press Release. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

COVID-19 Real-Time Learning Network. Vaccines & Immunity

Johnson & Johnson announces submission of application to the U.S. FDA for Emergency Use Authorization of its investigational single-shot Janssen COVID-19 vaccine candidate

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -United States

Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine -United States

Maintaining safety with SARS-CoV-2 vaccines

Accepted Article This article is protected by copyright. All rights reserved

Transmission of SARS-CoV-2 lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings -SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology. Virological

Emergence of SARS-CoV-2 B.1.1.7 lineage -United States

UK variant "may be more deadly

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Multisystem inflammatory syndrome in U.S. children and adolescents

Impact of COVID-19 Pandemic on Pediatrics and pediatric transplantation programs

COVID-19 vaccination provider requirements and support

COVID-19: When vaccine is limited, who gets vaccinated first

The importance of COVID-19 vaccination for healthcare personnel

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Factors associated with COVID-19-related death using OpenSAFELY

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry

Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort

Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine

COVID-19: People with certain medical conditions

Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients

Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients

Outcomes following SARS-CoV-2 infection in liver transplant recipients: An international registry study

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question

Hepatitis B and C in African Americans: current status and continued challenges

Nonalcoholic steatohepatitis: a review

Hepatitis B vaccination. Response of alcoholic with and without liver injury

Accepted Article This article is protected by copyright. All rights reserved

Immunogenicity of hepatitis A vaccine in decompensated liver disease

Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

New Brazil data shows disappointing 50.4% efficacy for China's CoronaVac vaccine. Reuters

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

The attenuated virus binds to the ACE2 for cell entry 3. mRNA is released into the cytoplasm 4. Ribosomes and cellular proteins are used to translate the mRNA into the spiked protein 5. The spike protein gets expressed on the cell surface and/or secreted into the serum 6. The spike proteins expressed on the cell surface by the MHC receptors can activate T-cells, which can activate the immune system

Antigen presenting cells can engulf secreted spiked proteins, which can also activate the immune system

ACE2: angiotensin-converting enzyme 2; MHC: major histocompatibility complex

The authors would like to acknowledge the AASLD staff and the AASLD Governing Board for their contributions to and support of this paper: 

This article is protected by copyright. All rights reserved